Sartorius and Science magazine to award prize for regenerative medicine and cell therapy
Award entails publication in Science magazine and prize money of U.S. $25,000 Exceptional scientists are invited to apply Goettingen, Germany, August 14, 2017 – Sartorius, a leading international pharmaceutical and...
IntelliCyt Launches Novel Assay System to Accelerate Cell Line Development
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals. Albuquerque, New...
NEW QSol Buffer Can Help Scientists Gain Insight From Challenging Samples
IntelliCyt is pleased to introduce the QSol buffer. Scientists need the most physiologically-relevant models to understand complex disease states. Sticky primary cells, highly concentrated samples, or large numbers of samples...
IntelliCyt Acquired by Sartorius
Acquisition Substantially Strengthens Premier Portfolio of Life Sciences Research Tools for Cell Analysis and Bioprocessing June 28, 2016 (Albuquerque, NM) – IntelliCyt, a leading provider of integrated platforms that accelerate...
Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
Developing predictive drug sensitivity assays using cancer patient cells is one of the promises of personalized medicine. Next generation platforms must integrate immune profiling in physiologically relevant ex-vivo microenvironments to...
IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
The state-of-the-art iQue Screener PLUS platform is optimized for high throughput and high content functional and phenotypic profiling of single cells in suspension. This new configuration allows researchers to benefit...
Massachusetts General Hospital enters into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
CRISPR/Cas9 genome editing technology holds great promise for identifying therapeutic drugs targets. Through high-throughput CRISPR functional screening, improving drug selection is expected to ultimately result in better, safer, more efficacious...
Frost & Sullivan Applauds IntelliCyt’s iQue® Screener Platform for Revolutionizing Drug Development and Disease Research
Use of the iQue Screener to better understand the biological mechanisms of disease early in the drug discovery process is expected to lower cost, improve lead selection and ultimately result...
AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
Albuquerque, NM, US and Cambridge, UK – May 10, 2016. IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery and immuno-oncology research today announced a collaboration...
Genetic Engineering News | Feature Article – Flow Cytometry Crystal Gazing
Excerpted from editorial: “Flow cytometry may play an important role in the evolution of personalized medicine. “The future of medicine will be to personalize by understanding a patient’s unique physiology...
IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
Albuquerque, New Mexico and Helsinki, Finland – February 25, 2016 IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research today announced a collaboration with the Institute...
IntelliCyt Corporation Announces Record 2015 Sales
Albuquerque, New Mexico – January 25, 2016 Business Wire – IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research, today announced record sales results for...
IntelliCyt Corporation Completes $7.4 Million in New Financing
Albuquerque, New Mexico – October 22, 2015 PRWeb – IntelliCyt Corporation (“IntelliCyt”), a leading provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology, announced it has completed $7.4 million...
SpectraGenetics joins IntelliCyt’s Technology Alliance Partner Program
Albuquerque, New Mexico – August 17, 2015 – IntelliCyt Corporation, the leading provider of innovative, high-throughput, high-content cell and bead-based screening solutions today announced its latest TAP awardee and partner,...
Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
Albuquerque, New Mexico and Basel, Switzerland – June 17, 2015 – Genedata and IntelliCyt today announced an alliance that brings together the market-leading strengths of each company to transform screening...
IntelliCyt launches iQue Screener PLUS
Albuquerque, New Mexico – May 9, 2015 – IntelliCyt Corporation, a leading developer of integrated solutions that accelerate drug discovery and life science research, today announced the launch of the...
IntelliCyt Corporation Wins ELRIG’s Best Technology Award
Albuquerque, NM – December 30, 2014 (PRWEB) IntelliCyt Corporation was recently named winner of the Best Technology Award at European Laboratory Robotics Interest Group’s (ELRIG) 4th Annual Pharmaceutical Flow Cytometry...
IntelliCyt Corporation Announces Technology Access Program
Albuquerque, NM (PRWEB) October 23, 2014. IntelliCyt Corporation, a leading provider of innovative, high-throughput, high-content cell- and bead-based screening solutions today announced the completion of the first Technology Access Program (TAP)...
Genetic Engineering News | Feature Article – Multiplying Multiplexing’s Power
Excerpted from editorial: “It can measure primary immune cell proliferation, isolate specific subtypes by immunophenotyping, and capture a secreted cytokine profile with encoded capture beads … all in the same...